Cubist +3.2% AH; FDA accepts Sivextro

|By:, SA News Editor

The FDA has approved Cubist's (CBST) Sivextro for "the treatment of adult acute bacterial skin and skin structure infections."

The company states Sivextro is "one of at least four antibiotics Cubist hopes to deliver" by 2020. A European Commission ruling on the drug is expected in 1H15.

Shares rose 5.4% in regular trading following news the FDA had granted priority review to an NDA for Cubist's investigational antibiotic ceftolozane/tazobactam"